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The androgen role in the maintenance of prostate epithelium is
subject to conﬂicting opinions. While androgen ablation drives the
regression of normal and cancerous prostate, testosterone may
cause both proliferation and apoptosis. Several investigators note
decreased proliferation and stronger response to chemotherapy of
the prostate cancer cells stably expressing androgen receptor
(AR), however no mechanistic explanation was offered. In this pa-
per we demonstrate in vivo anti-tumor effect of the AR on prostate
cancer growth and identify its molecular mediators. We analyzed
the effect of AR on the tumorigenicity of prostate cancer cells.
Unexpectedly, the AR-expressing cells formed tumors in male
mice at a much lower rate than the AR-negative controls. More-
over, the AR-expressing tumors showed decreased vascularity and
massive apoptosis. AR expression lowered the angiogenic potential
of cancer cells, by increasing secretion of an anti-angiogenic pro-
tein, thrombospondin-1. AR activation caused a decrease in RelA,
a subunit of the pro-survival transcription factor NFjB, reduced
its nuclear localization and transcriptional activity. This, in turn,
diminished the expression of its anti-apoptotic targets, Bcl-2 and
IL-6. Increased apoptosis within AR-expressing tumors was likely
due to the NFjB suppression, since it was restricted to the cells
lacking nuclear (active) NFjB. Thus we for the ﬁrst time identiﬁed
combined decrease of NFjB and increased TSP1 as molecular
events underlying the AR anti-tumor activity in vivo. Our data
indicate that intermittent androgen ablation is preferable to con-
tinuous withdrawal, a standard treatment for early-stage prostate
cancer.
' 2007 Wiley-Liss, Inc.
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Androgen withdrawal, common treatment for prostate cancer
(PrCa), frequently leads to androgen independence.1,2 Androgen
binding to AR facilitates AR dimerization and binding to the
androgen response element (ARE) CGTACAnnnTGTTCT and
transcription. In addition, AR mediates nongenomic androgen
effects, intracellular calcium ﬂux and kinase activation.3 In andro-
gen-independent cell lines, AR may cause cell growth in the
absence of ligand.4 Unlawful AR activation can occur without ste-
roids via surface receptors, like HER-2,5 or by growth factors, like
interleukin-6, oncostatin-M or bombesin.6,7 AR gene ampliﬁcation
can also lead to increased transcriptional activity.8 PTEN, a tumor
suppressor, along with membrane protein caveolin dampen AR
activity.9,10 Thus AR can be active even in low androgen environ-
ment. AR mutations cluster in an area that deﬁnes AR protein
interactions,11–13 they are rare in local disease14–16 but frequent in
metastases where they enable binding with estradiols, glucocorti-
coids and anti-androgens11,17 (reviewed in Ref. 17).
The role of androgens in cell survival and proliferation remains
controversial. In androgen-sensitive LNCaP cells, physiologic lev-
els of dihydroxytestosterone (DHT) fail to induce prostate-speciﬁc
genes but enhance growth, possibly via Rb phosphorylation,18 or
via CDK2, CDK4 and p16 genes19; moreover AR blocking agents
inhibit proliferation.20,21 Blocking AR with antisense oligonucleo-
tides, ribozymes, or Hsp90 hampers PrCa expansion.11 At the
same time, androgen may halt cell cycle via p27,18 and facilitates
differentiation,22 AR expression in null PC-3 cells causes growth
arrest, apoptosis and decreased invasion,23–30 and in DU145 cells,
growth arrest and differentiation.31 Moreover, AR activation by
mitogentic androgen doses sensitizes prostate cancer cells to the
cytotoxic insult by taxanes.32
High microvascular density (MVD) in PrCa marks poor progno-
ses and metastases.33 Testosterone stimulates endothelial prolifer-
ation and vascular regrowth (angiogenesis) after castration, how-
ever these may be secondary, due to hypoxia.34,35 In culture,
androgens stimulate angiogenic factors via HIF-1.36 The loss of
angiogenesis inhibitors in PrCa has been demonstrated,33,37 how-
ever direct androgen suppression was only shown for pigment epi-
thelial-derived factor (PEDF).37 Conversely, thrombospondin-1
(TSP1) is decreased or lost in hormone refractory disease.38
NFjB transcription factor is highly active in PrCa due to hyper-
active regulatory IjB kinase complex.39 NFjB promotes prolifer-
ation and inhibits apoptosis via c-myc, cyclin D, IL-6 and Bcl-2,
or by suppressing Bax.40 Noteworthy, in PrCa AR status inversely
correlates with NFjB activity.25,41,42
We analyzed how inducible AR affects the tumorigenicity of
AR-null PC-3 cells. Unexpectedly, the AR(1) PC-3 cells became
less tumorigenic on ambient testosterone background. Moreover,
AR(1) tumors displayed low MVD and massive apoptosis. The
diminished angiogenesis was due to elevated TSP1, while
increased apoptosis may be due to dramatically decreased NFjB
activity. AR expression lowered NFjB RelA, mRNA and protein,
and reduced RelA activity and nuclear localization. This, in turn,
dramatically decreased pro-survival Bcl-2 and IL-6. Thus we have




Bovine adrenal capillary endothelial cells (BAMVEC) were
grown in MCDB131 (Sigma) with supplements (BioWhittacker).
PC-3 were maintained in RPMI1640 (Invitrogen), 10% FBS and
1% Penicillin/Streptomycin. PC-3 cells expressing tetracycline
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(tet) repressor (PC3-TR) were grown in tet-free serum (HyClone),
and Blasticidin (1 lg/ml, Invitrogen).
To collect conditioned media (CM), 80% conﬂuent cells were
rinsed, incubated 48 hr in serum-free RPMI, media collected,
cleared of debris, and concentrated in Millipore Ultrafree ﬁlters
(5 kDa).
Cell growth was measured using WST-1 kit (Roche). The cells
were plated in 96-well plates (5 3 102 cells/well), and induced
with Doxycycline (Dox) (1 lg/ml, Fluka).
AR-inducible cells
We used T-REX inducible system (Invitrogen). The wild-type
AR cDNA (Dr. X. Liao, University of Chicago, IL) and AR-877
mutant (Dr. Z. Culig, Innsbruck Medical University, Austria) were
ampliﬁed, cloned into BamHI-Age I sites of pcDNA4/TO/myc-
His vector and veriﬁed by sequencing. PC-3 cells were transfected
with pcDNA6/TR (tet repressor) conferring Blasticidin resistance
(FuGENE6, Roche). Transfectants were screened with b-gal
reporter (pcDNA4/TO/lacZ, Invitrogen). PC3-TR cells were
transfected with pcDNA4/TO/myc-His-AR. Cells resistant to
Blasticidin/Zeocin were expanded and screened for AR expres-
sion. Clones with the lowest background expression were chosen
(PC3-V, PC3-ARWT, PC3-AR877).
Western blotting
The cells were lyzed in PBS, 1% NP40, 0.5% Na deoxycholate,
0.1% SDS, and protease inhibitor cocktail (Sigma). Cleared
lysates were resolved by SDS-PAGE and transferred to PVDF
membranes. After blocking (5% Blotto in TBS-T, 20 mM TBS,
pH7.4, 0.1% Tween-20) the membranes were probed and devel-
oped with ECL kit (Amersham). For IjB, total lysates were col-
lected, resolved by SDS-PAGE, transferred to PVDF, blocked and
probed in 0.5% BSA/TBS-T. For TSP1, CM (10 lg/lane) were
resolved by 8% SDS-PAGE, membranes blocked in 7% Blotto
and probed in 1% Blotto/PBS. For Bcl-2, membranes were
blocked in 10% Blotto/TBS-T. The antibodies were: AR rabbit
PAb (Ab-2, Santa Cruz), IjB-a rabbit PAb (Cell Signaling), TSP1
MAb (A4.1, Novus), Cytokeratin 8 pAb (Santa Cruz) and Bcl-2
antibodies (Santa Cruz). U19 antibodies were raised against GST-
fusion protein and puriﬁed as described.43
IL-6 measurement
IL-6 was detected in conditioned media (CM) collected as
above, using human IL-6 ELISA kit (BD Biosciences, San Diego,
CA), as recommended by the manufacturer.
RT-PCR
RNA were extracted with GenElute kit (Sigma), converted to
cDNA and ampliﬁed 30 cycles in 0.2 mM dNTPs, 1.5 mM MgCl2,
0.1 lM primers and 1 U Taq polymerase (Fermentas); 20 denatura-
tion (94C), 4500 annealing (55C for actin, IL-6 and NFjB,











Cells were plated (3 3 105/well) in 6-well plates, induced 24 hr
with 1.0 lg/ml Dox and transfected with 1 lg Fireﬂy luciferase
(FL) reporter, and 25 ng pRL-TK (Renilla luciferase, RL, Prom-
ega). R1881, (DHT), progesterone (Prg), ﬂutamide (Fl) (Sigma) or
vehicle (EtOH), were added for 24 hr. Luciferase activity was
FIGURE 1 – Characterization of AR-expressing cells. (a) Inducible expression of AR and regulated genes. PC-3 clones expressing ARWT and
AR877 were treated with Dox and DHT, where shown, lysates resolved by SDS-PAGE and Western blots probed for AR (top), AR-dependent
U19 (middle) and cytokeratin 8 (K8, bottom). (b) AR expression and localization was examined by IHC in similarly treated cells. (c) AR activity
was tested with ARE reporter. Note AR877 activation by DHT (R1887), Flutamide (Fl) and Progesterone (Prg). (d) Growth curves of PC3-ARWT
and PC3-AR877 generated in media with DHT, 6 Dox.
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measured using Dual Luciferase Reporter Assay (Promega).
Luminiscence was assessed with Monolight 2010 Luminometer
and the FL activity normalized against RL. Background (pGL3-
TATA-Luc vector) was subtracted and fold induction calculated.
The experiments were repeated in triplicate.
pGL3-TATA-Luc and AR reporter pGL3-GRE-Luc were form
Dr. C. Kao, University of Indiana, Indianapolis. For TSP1 we used
22033/1150 promoter fragment44 driving a RL reporter. The fol-
lowing AR/NFjB constructs were used: jB-FL reporter (5x jB
promoter, Dr. WC.Greene, Gladstone Institute, UCSF); MMTV-
FL reporter for steroid receptors, (Clontech, Palo Alto; CA);
pcDNA3.1-CMV-p50 and pcDNA3.1-CMV-p65 (Dr. S. Okret,
Karolinska Institutet, Sweden); pcDNA3.1-CMV-AR (Drs. O.A.
Janne and J.J. Palvimo, University of Helsinki, Helsinki, Finland);
and pcDNA-CMV-dnIjB-a (Dr. I.Verma, Salk Institute, La Jolla,
CA).
For NFjB assays, 50% conﬂuent PC-3 or LNCaP were trans-
fected with indicated plasmids. After 36 hr the cells were
harvested and Luciferase activity measured. Where shown, the
cells were pre-treated 24 hr with DHT (Sigma).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using
E-ZChIP kit (Upstate). Formaldehyde was added (ﬁnal 1%,
10 min, 37C), the cells washed in PBS, lyzed in 1% SDS, 10 mM
EDTA, 50 mM Tris pH 8.1 and sonicated to produce 1 Kb DNA
fragments. The samples diluted 1:10 in 0.01% SDS, 1.1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 150 mM
NaCl, were incubated with AR antibody (1:500, BD Biosciences).
DNA/protein complexes were isolated on salmon sperm DNA
agarose and extracted with 1% SDS, 0.1M NaHCO3. Crosslinking
was reversed, proteins digested with proteinase K and removed.
DNA was precipitated, re-dissolved and ampliﬁed with TSP1 pri-
mers localized to the 1st intron (50-30): TGAGGCTTCAGTC-
CCTCTGGT and AGTACAGACTCTTCCCTGAGTGCT (225 bp).
Migration assay
Migration assay was performed as in Ref. 45. BAMVECs
starved in MCDB131, 0.1% BSA (Sigma), were plated at 1.5 3
106 ml21 in Boyden chambers on the lower surface of gelatinized
membranes (8 lm, Nucleopore). After attachment, serial dilutions
FIGURE 2 – The effect of inducible AR expression on the prostate carcinoma in vivo. (a) Male nude mice with ﬂank injections of PC3-V,
PC3-ARWT and PC3-AR877 received Dox (m) to induce AR expression, or plain drinking water (n). The expression and nuclear localization of
AR has been conﬁrmed by IHC (insets). Note delayed tumorigenesis by AR(1) cells. (b) Male nude mice were all treated with Dox and received
ﬂank injections of tumor cells as in (a). Half of the animals was treated with Fl (), another half with vehicle (s). Note restored growth of PC3-
ARWT by Fl compared to the control and the lack of response to Fl by PC3-AR877. (c) Female nude mice received ﬂank injections of PC3-V and
PC3-ARWT, as in (a). The animals received Dox () or plain water (s). One half of the animals implanted with PC3-ARWT were given DHT
implants. Note the lack of growth inhibition by AR (Dox) in the absence of DHT and the delayed growth in Dox-treated animals bearing DHT
implants.
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of CM from PC3-V, PC3-ARWT or PC3-AR877 were placed in top
wells for 4 hr. Background migration (BSA) was subtracted and
the data presented as percent maximal migration (10 ng/ml
bFGF). All samples were tested in quadruplicate.
Tumorigenicity assay
PC3-V, PC3-ARWT or PC3-AR877 cells were injected s.c. in
hindquarters of athymic male mice (nu/nu, National Cancer Insti-
tute, 4–6 weeks), 106 cells/site, 5 animals/group, 2 sites/animal.
To induce AR expression, Dox (1mg/ml) was given in drinking
water. The tumors were measured every 3 days and the volumes
calculated as length 3 width2 3 0.52. The experiment was
repeated using the same numbers of female athymic mice 6 DHT
pellets. The pellets were generated in the lab as described in
Ref. 43. Flutamide (Fl) (40 mg/kg, Sigma) was given daily p.o. At
the endpoint tumors were removed, snap-frozen or ﬁxed in 4%
formaldehyde. The animals were handled following the National
Institute of Health guidelines, protocols approved by Northwestern
University Animal Care and Use Committee.
Immunostaining
Five micrometer cryosections were ﬁxed in cold acetone, 1:1
acetone/chloroform and acetone (10 min ea), rinsed in PBS,
blocked with Avidin-Biotin Blocking kit, mouse Ig (Vector) and
incubated 30 min with rat CD31 (1:125, PharMingen) and mouse
TSP1 antibodies (1:100, Neomarkers). The slides were washed in
PBS and incubated 15 min with donkey anti-rat RhodamineX
antibodies (1:200, Jackson Immunoresearch) and biotinylated
anti-mouse antibodies (1:200, Vector). Slides were developed
with FITC-conjugated Avidin D (20 lg/ml, Vector). Biotinylated
anti-rabbit antibodies were applied in blocking solution (1:200, 30
min) and followed by 1 lg/ml Streptavidin-Cy5 (Jackson Immu-
noresearch). To visualize apoptosis, the sections were evaluated
by TUNEL (ApopTag kit, Serologicals).
For AR, 5 lm sections were deparafﬁnized, rehydrated, washed,
antigen retrieved 15 min at 20–25 psi, 100C in citric buffer pH
6.0 and 20 min at room temperature. Endogenous peroxidase was
inhibited with blocking solution (Dako) and AR antibody added
(30 min, N-20, Santa Cruz, 1:200) followed by HRP-conjugated
anti-rabbit antibodies (30 min). Slides were developed with diami-
nobenzidine and counterstained with hematoxylin. Nonimmune
rabbit serum served as negative control.
For NFjB, the sections after antigen retrieval were blocked
with 20% goat serum in PBS, and incubated with mouse mAb for
human p65/RelA (Cell Signaling), followed by ﬂuorescent goat
anti-mouse Ab (Jackson Immunoresearch). Representative ex-
periments of 4 are shown.
Image quantiﬁcation
Fluorescent images were obtained using Nikon ﬂuorescent
microscope (Diaphot 200) and converted to digital ﬁles using
MetaMorph software. The same software was used to measure ﬂu-
orescence intensity and compare the values to DAPI counterstain
used as background. CD31-positive structures (MVD) were
counted in 10 403 ﬁelds using MetaMorph software. Apoptotic
FIGURE 3 – AR-expressing tumors showed increased apoptosis and decreased MVD. (a) Parafﬁnized tumor sections were stained with H&E
(left) and snap-frozen sections (right) for endothelial marker CD31 (red) and apoptosis (TUNEL, green). To conﬁrm AR functional activity, the
same sections were stained for U19 (blue). (b) Quantitative analysis of MVD. (c) Endothelial cell apoptosis calculated as percent of TUNEL-
positive of total CD31-positive structures (merge, yellow). (d) Tumor cell apoptosis (total TUNEL-positive cells minus TUNEL positive endo-
thelial cells). All measurements were performed with MetaMorph software.
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cells were quantiﬁed in 10 random ﬁelds using MetaMorph
software.
Statistical analysis
Mean and standard error values were calculated and compared
using paired Student’s t test and ANOVA. p values < 0.05 were
considered signiﬁcant.
Results
AR induction reduced tumorigenicity
We generated PC-3 cells inducibly expressing wild-type AR
(PC3-ARWT) and promiscuous AR T877A46 (PC3-AR877)
(Fig. 1a). Induced AR levels were comparable to LNCaP cells
(not shown). The AR axis was restored and two AR-dependent
genes, U1943 and cytokeratin 847 robustly induced upon AR acti-
vation (Fig. 1a). Both wild-type and mutant AR became nuclear in
the presence of DHT (Fig. 1a) and induced transcription of the
ARE-luciferase reporter (Fig. 1c). AR877 was also activated by
Flutamide and progesterone (Fig. 1c). The expression and nuclear
localization of AR were induced in vivo in the PC-3 cells
implanted in male mice upon Dox treatment (Fig. 2a, insets).
However AR re-expression failed to enhance PC-3 growth in
response to DHT (Fig. 1d). Moreover, AR(1) cells were less
tumorigenic in male mice in the presence of Dox (Fig. 2a). When
we used oral Flutamide to block endogenous testosterone, PC3-
ARWT regained tumorigenicity while PC3-AR877 did not (Fig.
2b), suggesting that weak activation by Fl was sufﬁcient to sup-
press tumor growth. Finally, PC3-ARWT cell formed tumors in
Dox-treated female mice, obviously lacking endogenous testoster-
one, but not when they received DHT implants, underscoring the
repression by androgen (Fig. 2c).
AR(1) PC-3 tumors had lower MVD and higher apoptosis rate
We measured MVD in the AR(1) and AR(2) PC-3 tumors.
PC3-ARWT and PC3-AR877 tumors in Dox-treated animals had
2.2–2.6 times lower MVD (p < 0.01) than untreated controls, or
the AR(2) controls (Figs. 3a and 3b). TUNEL showed more endo-
thelial and nonendothelial apoptotic cells in the AR(1) PC-3
tumors (Figs. 3a, 3c and 3d). AR remained functional in these
tumors: its localization was predominantly nuclear in Dox treated
FIGURE 4 – AR decreased angiogenesis via angioinhibitory TSP1. (a) RT-PCR detection of TSP1 mRNA in PC3-V, PC3-ARWT and PC3-
AR.877 Note decreased TSP1 mRNA by Fl in PC3-ARWT but not AR.877 (b) Western blot of Conditioned Media from PC3-V, PC3-ARWT and
PC3-AR877 6 Dox. All cells were DHT-stimulated. (c) The induction of TSP1-Luc reporter in AR(1) and control cells. (d) ChIP of the putative
ARE in the 1st intron of TSP1 gene. IC: isotype control. PCR control: cloned TSP1 promoter ampliﬁed with the same primers. DNA input is
shown. (e) Endothelial cell chemotaxis with the CM from PC3-V, PC3-ARWT and PC3-AR877. The cells were treated with Dox and stimulated
with DHT, where indicated and the CM collected and tested at increasing concentrations with the TSP1 neutralizing antibody () or with iso-
type control antibody (IgA) (s). Note the that CM from AR(1) cells are less potent at inducing endothelial cell chemotaxis, and that TSP1 neu-
tralizing antibody, but not isotype control improves migration (arrowheads). (f) Immunostaining of the PC3-V, PC3-ARWT and PC3-AR877
tumors in control and Dox-treated male mice. Cryosections were stained for CD31 (red) and TSP1 (green).
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males (Fig. 2a) and, AR responsive protein, U19 was strongly
upregulated (Fig. 3a). Thus restoring AR axis in the androgen-
insensitive cells delayed tumor progression, lowered MVD and
increased apoptosis.
AR activation upregulated angioinhibitory TSP1
Seeking AR-dependent changes affecting MVD, we investi-
gated angiogenic mediators in AR(1) and AR(2) cells. Three
pro-angiogenic cytokines, VEGF, bFGF and IL-8, previously
identiﬁed in PrCa,36,48–53 remained unaltered. We were unable to
detect changes in VEGF mRNA or protein using quantitative
RT-PCR, ELISA, or immunostaining (data not shown). TSP1 is a
critical angiogenesis inhibitor, whose expression is signiﬁcantly
lower in cancerous compared to the normal prostate51,54; an index
integrating TSP1 with angiogenesis independently predicts sur-
vival.52 In our model, TSP1 was low in parental PC-3 and PC3-V
cells. In PC3-ARWT and PC3-AR877, TSP1 mRNA and secreted
protein became high upon Dox/DHT stimulation (Figs. 4a and
4b). In PC3-ARWT Dox/DHT increased activity of the luciferase
reporter containing 22033/1150 TSP1 promoter fragment44
(Fig. 4c). Moreover, ChIP demonstrated AR binding to the TSP1
promoter (Fig. 4d).
TSP1 suppressed angiogenesis in AR(1) cells
The migration of endothelial cells up the gradient of angiogenic
factors is an important component of angiogenesis and an indica-
tor of angiogenic activity of a given cell line.55 The majority of
natural inhibitors block endothelial cell chemotaxis induced by
VEGF or by bFGF. To determine if TSP1 was responsible for the
decrease of angiogenesis in AR(1) tumors, we examined endothe-
lial cell chemotaxis to CM from the PC3-V and PC3-AR. PC3-V
CM induced migration, with or without Dox and/or DHT, with
EC50 5 2.4 lg/ml. CM from nonstimulated PC3-AR
WT and PC3-
AR877 were also angiogenic, with similar EC50 (1.9–2.2 lg/ml),
and not signiﬁcantly altered by TSP1 antibodies (Fig. 4e). How-
ever, CM from PC3-ARWT and PC3-AR877 stimulated to express
AR and activated with DHT became less angiogenic (EC50 > 10
lg/ml). This lower angiogenic activity was due to TSP1, since
TSP1 neutralizing antibody restored angiogenic activity (Fig. 4e).
IHC showed MVD reduction in AR(1) tumors, paralleled by a
FIGURE 5 – The interference between AR and NFjB. (a) Reporter assays in cells transfected with the combination of NFjB-Luc, ARE-Luc,
AR or p65/p50. pcDNA-neo was used to equalize the total DNA input. DHT (black bars) or control vehicle (ethanol: gray bars), where added,
where indicated. Note decreased NFjB activity in the PC3-AR and increased AR activity in the presence of dnIjBa (NFjB superrepressor). (b)
PC3-ARWT cells were treated with Dox or Dox/DHT, nuclear extracts collected and analyzed by EMSA. Cold probe (Comp) or IKK inhibitor,
BMS345543 (10 lM, BMS) added where indicated. (c) Total IjB-a in Dox/DHT stimulated cells. PC3-V -ARWT and -AR877 cells were treated
for 24 hours with vehicle ethanol or DHT, as indicated, and IjB-a detected in total cell lysates by Western blot. The blot was re-probed for b-
tubulin to assess loading (lower panel). (d) RT-PCR of p65 (RelA) mRNA in similarly treated cells. Note a decrease upon AR activation. (e)
PC3-ARWT cells were grown on coverslips, treated as indicated and stained for AR (top) or NFjB (bottom). Note the lack of nuclear NFjB
upon DHT stimulation. (f, g) IL-6 levels in Dox/DHT stimulated cells. The cells were treated as in (c), total RNA collected and RT-PCR per-
formed with primers for IL-6 (F). C1, no cDNA; C2, no primers. (g) IL-6 detected by ELISA, in the media conditioned by similarly treated cells.
(h) Western blot for Bcl-2.
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dramatic increase in TSP1 (Fig. 4f), pointing to a similar course of
events in vivo.
AR activation lowered NFjB levels and activity
Seeking reasons for the decreased viability/increased apoptosis
in AR(1) tumors we investigated NFjB status of AR(1) and (2)
PC-3 populations. Constitutive NFjB activation and subsequent
Bcl-2 increase mark hormone refractory PrCa.42,56,57 Conversely,
AR and NFjB counteract in transcription assays.58 Indeed, re-
porter assays showed high basal NFjB activity in PC-3 cells,
which was decreased upon transient transfection with ARWT and
diminished further by DHT (Fig. 5a, left). Moreover, ARE-Luc re-
porter activity, moderate in PC3 transfected with ARWT, doubled
in DHT-treated cells when NFjB was blocked with dnIjB-a
(Fig. 5a, center). Conversely in AR-sensitive LNCaP p50/p65 dra-
matically reduced ARE-Luc transactivation, with or without DHT
(Fig. 5a, right). EMSA showed that DHT signiﬁcantly reduced
NFjB DNA binding in PC3-AR cells (Fig. 5b). NFjB is chieﬂy
regulated via cytoplasmic retention by IjB-a. However, the IjB-
a levels in the AR(1) cells showed only modest increase, after
Dox treatment (Fig. 5c) Unexpectedly, DHT signiﬁcantly
decreased the RelA mRNA in PC3-AR but not in PC3-V cells
(Fig. 5d).
In addition, in PC3-ARWT and AR877, DHT lowered nuclear
p65/RelA (Fig. 5e and data not shown). Nuclear localization of
AR and p65 were mutually exclusive: in PC3-ARWT, AR was pre-
dominantly cytoplasmic in the absence of DHT, while p65 was
mostly nuclear. Conversely, in DHT-treated cells AR was predom-
inantly nuclear, while p65 became cytoplasmic (Fig. 5e).
AR blocked pro-survival NFjB targets
DHT severely decreased the two NFjB targets, IL-6, as was
measured at mRNA level and secreted protein (Figs. 5f and 5g),
and Bcl2 (Fig. 5h). Both proteins are capable of increasing cell
survival.
AR diminished nuclear NFjB and increased
apoptosis in vivo
The decrease in active NFjB remained true in vivo. While
AR(2) tumors showed NFjB staining in the cytoplasm and
nuclei, in AR(1) tumors RelA resided mainly in the cytoplasm
(Fig. 6a). Similar to the in vitro results, RelA immunoreactivity
was much weaker in AR(1) tumors (Figs. 6a and 6c). Higher inci-
dence of nuclear NFjB was accompanied by low apoptosis rates,
while in Dox-treated male mice AR(1) tumors showed less
nuclear NFjB and higher apoptosis (Figs. 6b and 6d).
Discussion
Current in vivo models include tumor grafting in syngeneic or
immune compromised animals, or autochthonous tumors in genet-
ically manipulated mice. The differences in structure, physiology
and cancer progression in mouse and human prostate59 make it
essential to complement the ﬁndings from genetically altered mice
with those from xenografted tumors. Indeed, stroma and the
smooth muscle are major structural and functional components in
human, but not in mouse prostate. Lobular structure is seen in the
mouse but not in human prostate, while mice have no transitional
zone, prostatic urethra and capsule.59 Most importantly, prostate
cancer does not occur spontaneously in wild-type mice; the major-
FIGURE 6 – AR effect on NFjB nuclear localization and apoptosis in vivo. (a, c) Immunostaining of AR(1) (PC3-AR) and control (PC3-V)
tumors for p65 (RelA). The mice were given drinking water 6 Dox, the resultant tumors stained for RelA (NFjB, red). (a) Representative
images of the stained sections. Note nuclear RelA (solid arrowheads) in the absence of Dox and the lack of nuclear staining in Dox-treated
tumors (empty arrowheads). (c) Immunoﬂuorescence intensity was measured using MetaMorph software in a minimum of 12 random ﬁelds on 3
independent sections. (b, d) Inverse correlation between nuclear NFjB localization and apoptosis. Sections of Dox-treated or untreated (control)
AR(1) tumors were stained for RelA (NFjB, red). Apoptosis was visualized by TUNEL (green). (b) Representative images of the stained
sections. Upper panels show merged images. Empty arrowheads indicate cells lacking nuclear RelA. (d) TUNEL-positive cells were quantiﬁed
in 6 random ﬁelds, 3 independent sections.
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ity of mouse models are driven by SV-40 large and small T viral
oncogenes. Other suspect oncogenes and tumor suppressors yield
intraepithelial neoplasia (PIN) but not PrCa.60 Only three genes
have been found critical for prostate carcinogenesis in mice: an
oncogenic IGF-1 and cMyc, and a tumor suppressor PTEN.61,62
Surprisingly, AR failed as prostate-speciﬁc oncogene in trans-
genic models, its overexpression yields PIN but no invasive carci-
noma.63 In another study, wild-type and promiscuous AR mutant
T857A (T877A analogue) fail to induce PIN in young animals
suggesting that ligand driven AR activation does not induce epi-
thelial hyperproliferation in the whole prostate.64 Thus androgen
role in PrCa is not unequivocal. In normal prostate it likey main-
tains homeostasis of proliferation vs. apoptosis, while androgen
ablation changes AR targets from apoptotic to survival/prolifera-
tion. Interestingly, studies form Liao and coworkers demonstrate
that AR-positive LNCaP cells, conditioned by long-term androgen
withdrawal become hypersensitive to androgen and could be sup-
pressed by androgen in vivo65 and identify decreased cMyc and
increased Bax as responsible genes.66 Moreover. LNCaP sublines
rendered androgen-independent, could be suppressed by androgen
and then reversed to androgen-dependent phenotype.67
According to Greenberg and coworkers, transgenes encoding
either AR-WT or AR-T857A, a mouse analog of human T877A
mutant, did not cause prostate cancer in mice.64 Consistent with
their data, we showed that inducible wild-type and T877A AR
failed to expedite tumor progression in a subcutaneous xenograft
model, but instead caused dramatic delay in tumor progression,
decreased MVD and increased apoptosis. Interestingly, these
changes occurred predominantly in vivo. Other investigators
observed decreased proliferation upon re-expression of AR,26
however in our hands, AR(1) and (2) cells in vitro grew at the
same rate. This difference may be due to the use of inducible AR
expression, while stable transfectans may have acquired additional
changes due to the constitutive AR overexpression. The molecular
effects of AR expression/activation in PC-3 cells were twofold:
decreased activation of NFjB, a pro-survival transcription factor
in prostate epithelium,40,56,57 and decreased overall angiogenic
activity due to increased angioinhibitory TSP1, which translated
into AR-dependent decrease of tumor MVD. The inverse correla-
tion between TSP1 levels and prostate cancer progression and vas-
cularization has been previously shown,33,51,52,54 however TSP1
induction by AR has not been demonstrated.
The crosstalk between AR and NFjB has been previously
shown in vitro, where NFjB inactivation resulted in higher apo-
ptosis rates.25,68 However, others indicate that AR also may
increase NFjB activity.69,70 Despite NFjB blockade, AR expres-
sion failed to increase apoptosis in vitro. Increased tumor apopto-
sis in vivo suggests that NFjB deactivation lowered the survival
of AR(1) cells under stress. This is consistent with potentiated
response to genotoxic stress by AR.24 In our system AR(1) cells
low in NFjB activity, become apoptotic in response to hypoxia
due to insufﬁcient angiogenesis. Conversely, AR(2) cells remain
resistant. In addition, NFjB may contribute to the angiogenic
properties of prostate epithelium by increasing NOS and cycloox-
ygenase-271: its inactivation would further reduce tumor MVD.
It is widely accepted that functional AR is expressed in a large
portion of advanced prostate cancers. However the majority of AR
pathway genes (HERPUD1, STK39, DHCR24, and SOCS2) are
suppressed in metastatic prostate cancer,72 underscoring the fact
that many of the AR targets counter cancer progression.
Our study indicates that both wild-type AR and AR with altered
ligand speciﬁcity, lack the ability to transform prostate epithelium.
Conversely, Greenberg and coworkers identiﬁed carcinogenic AR
mutations in the transactivation domain.73 Interestingly, somatic
mutations associated with male infertility are in the DNA and lin-
gand binding domains and the hinge, while 40% cancer-associ-
ated mutations are in the transactivation domain, where they affect
cofactor interactions. Although >80% AR point mutations have
been identiﬁed in cancer specimens, their functional consequences
are not veriﬁed, except for a few isolated cases. Combined data by
Greenberg’s group64 and our’s suggest that while AR maintains
interactions with proper coactivators and corepressors, it continues
to control homeostatic proliferation, apoptosis, and angiogenesis.
One possible explanation is the release of AR control over NFjB
activity: once disrupted, NFjB activation, in turn, favors increased
survival, dampens stress responses and favors tumor progression.
The mechanism of AR interference with NFjB remains unclear:
although weak AR/NFjB interaction was observed in vitro,74 the
result has never been reproduced. Other investigators suggest
competitive binding to adjacent cis-regulatory elements on the
DNA.75 We observed modest IjB-a increase in the AR(1) cells,
however higher RelA mRNA and protein levels are more likely to
play a role. Indeed, DHT stimulation on the AR(1) tumors pro-
duced the decrease in general NFjB immunoreactivity.
Our results suggest that persistent androgen ablation promotes
the progression to androgen independent phenotype and indicate
possible beneﬁts of the treatment where androgen application and
ablation are used in succession or intermittently.
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